Outlook Therapeutics® to Present at the BTIG Ophthalmology Day
November 22 2022 - 08:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company working to develop and launch the first FDA-approved
ophthalmic formulation of bevacizumab for use in retinal
indications, today announced that Russ Trenary, President and Chief
Executive Officer of Outlook Therapeutics, will present in a
fireside chat at the virtual BTIG Ophthalmology Day on November 29,
2022 at 12:30 PM ET.
In addition to the presentation, management will
be available to participate in virtual one-on-one meetings with
qualified members of the investor community who are registered to
attend the conference.
BTIG hosted events are intended for prospective and existing
BTIG clients only. To listen to the live event, please contact your
BTIG representative with interest.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical
company working to develop and launch ONS-5010/ LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab for use in retinal indications, including wet AMD,
DME and BRVO. The FDA accepted Outlook Therapeutics’ BLA submission
for ONS-5010 to treat wet AMD with a PDUFA goal date of August 29,
2023. The submission is supported by Outlook Therapeutics’ wet AMD
clinical program, which consists of three clinical trials: NORSE
ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab
is approved, Outlook Therapeutics expects to commercialize it as
the first and only FDA-approved ophthalmic formulation of
bevacizumab for use in treating retinal diseases in the United
States, United Kingdom, Europe, Japan, and other markets. For more
information, please visit www.outlooktherapeutics.com.
CONTACTS:Media Inquiries:Anna
ArmyAccount SupervisorLaVoie Health ScienceT:
617-351-0246aarmy@lavoiehealthscience.com
Investor Inquiries:Jenene ThomasChief Executive
OfficerJTC Team, LLCT: 833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Nov 2023 to Dec 2023
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Dec 2022 to Dec 2023